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Summary 
Tumor necrosis factor (TNF) ot is a cytokine that has potent immune regulatory functions. To 
assess the potential role of this cytokine in the early development of autoimmunity, we investigated 
the effect of TNF on the development of insulin-dependent diabetes mellitus (IDDM) in nonobese 
diabetic (NOD)  mice,  a spontaneous murine  model for autoimmune,  insulin-dependent  type 
I diabetes. Treatment  of newborn female NOD mice with TNF every other day for 3 wk, led 
to an earlier onset of disease (10 versus 15 wk of age in control mice) and 100% incidence before 
20 wk of age (compared to 45%  at 20 wk of age in control phosphate-buffered saline  treated 
female mice). In contrast, administration of an anti-TNF monoclonal antibody, TN3.19.12, resulted 
in complete prevention of IDDM.  In vitro proliferation assays demonstrated that mice treated 
with TNF  developed an increased T  cell response to a panel of B cell autoantigens,  whereas 
anti-TNF treatment resulted in unresponsiveness to the autoantigens.  In addition, autoantibody 
responses to the panel of B cell antigens paralleled the T  cell responses.  The effects mediated 
by TNF appear to be highly age dependent.  Treatment  of animals  either from birth  or from 
2 wk of age had a similar effect. However, if treatment was initiated at 4 wk of age, TNF delayed 
disease onset.  These  data  suggest  that  TNF  has  a  critical  role in  the  early development  of 
autoimmunity  towards  B-islet cells. 
T 
NF has been the focus of intensive study because of its 
involvement  in  many  physiological  and  pathological 
processes.  It is now clear that  TNF  is produced predomi- 
nantly by activated macrophages and occasionally by other 
cell types such as CD4 + T  cells, predominantly of the Thl 
subset (1-3). Furthermore,  the broad range of expression of 
its receptors suggests that TNF has a number of biological 
activities in a wide variety of cells  and tissues (4).  Impor- 
tantly, a role for TNF has been found in virtually all inflam- 
matory diseases or lesions and it is therefore believed that 
TNF is a major mediator  of inflammation. 
Insulin-dependent  diabetes  mellitus  (IDDM) 1  is  a  T 
cell-mediated chronic autoimmune disease that is character- 
1 Abbreviations used in  this paper: CPH,  carboxypeptidase-H; GAD, 
glutamic acid decarboxylase; HEL, hen egg lysozyme; HSP60, murine 
60-kD heat-shock protein; IDDM, insulin-dependent diabetes mellitus; 
MNC, mononuclear cell; NOD, non-obese  diabetic; TNF, tumor necrosis 
factor et. 
ized by lymphocytic infiltration  of the pancreatic  islets of 
Langerhans  and  by  the  selective  destruction  of insulin- 
producing B cells in the islets.  Since TNF is a proinflamma- 
tory cytokine and its gene is localized within the MHC, which 
has been shown to have a strong genetic linkage to several 
autoimmune disorders including IDDM, TNF has been con- 
sidered to be a possible candidate cytokine mediating the patho- 
genic destruction of B-islet cells. Earlier studies have provided 
two sets of conflicting evidence regarding the function(s) of 
TNF in IDDM. The first set of evidence suggests that TNF 
has an active role in the pathogenesis of IDDM. This is based 
on the finding that TNF mRNA is produced by CD4 + T 
cells in situ in inflamed islets of nonobese diabetic (NOD) 
mice  (5)  and  that  in  the presence  of other  inflammatory 
cytokines such as IL-1 or IFN-v, TNF in vitro mediates cy- 
totoxicity to pancreatic islets (6-9). Recently, it has been shown 
that transgenic mice expressing TNF in the pancreatic B cells 
under  the control of the rat-insulin  promoter  (RIP-TNF) 
exhibit massive lymphocytic infiltration of the islets (but were 
free of overt diabetes) indicating that TNF is an important 
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mation (10, 11). In contrast, the second set of evidence shows 
that strains of autoimmune-prone mice, such as NOD and 
New Zealand black/white (NZB/NZW), appear in some in 
vitro assays to have a reduced ability to produce TNF. It has 
been shown that peritoneal macrophages from NOD mice 
and bio-breeding (BB) rats, both of which develop  sponta- 
neous IDDM, and from NZB/NZW mice, a murine model 
of autoimmune lupus, produce less TNF upon in vitro stim- 
ulation with LPS than other nonautoimmune-prone inbred 
strains (12-14).  Thus, it is believed that this reduced produc- 
tion of TNF may play a role in the diabetogenic process (12). 
Further studies (12-16) have demonstrated that treatment of 
adult animals with subtoxic doses of recombinant TNF can 
lead to prevention of spontaneous IDDM or to prolonged 
survival  of mice with murine lupus. 
Several recent studies have provided some interesting in- 
sights into the function of TNF in the development of the 
immune system. Giroir et al. (17) have shown that in trans- 
genic mice which carry the reporter gene chloramphenicol 
acetyl transferase  (CAT) coupled to the TNF promoter, ex- 
pression of the CAT gene is detected very early during thymic 
development and for the first 3-4 wk of neonatal life. Fur- 
thermore, the thymus seems to be the only organ constitu- 
tively producing TNF.  Using an anti-TNF polyclonal an- 
tiserum,  De  Kossodo et  al.  (18) have  demonstrated that 
blocking TNF function during early development results in 
thymic and splenic atrophy and lymphopenia. Together, these 
data strongly suggest that TNF is an important cytokine for 
thymic development and it may be at this level that TNF 
influences the development of autoimmunity. 
In an attempt to clarify these controversial findings and 
to gain a better understanding of the role of TNF in the de- 
velopment of autoimmunity and in the regulation of autoim- 
mune responses  to target organs, we have studied the effect 
of TNF and anti-TNF treatment in newborn and young NOD 
mice on the pathogenesis of IDDM  (19). 
Materials and Methods 
Mice.  NOD/McD (K d, I-A  gT, D  b) mice were initially obtained 
from Dr. E. Leiter at The Jackson Laboratory (Bar Harbor, ME) 
and were subsequently bred and raised at the Stanford University 
Animal Facility  under barrier isolation  conditions. The spontaneous 
incidence of diabetes in the colony is currently 70-80% in females 
and 10-20% in males by 30 wk of age. 
Cytokines and mAbs.  Recombinant murine TNF and IFN-y 
were kindly provided  by Genentech Inc. (South San Francisco,  CA). 
The activity and concentration of TNF was 1.2  x  107 U/ml and 
0.98  mg/ml;  IFN-3/ was  5.2  x  106  U/ml  and  1  mg/ml. 
TN3.19.12 (hamster IgG1), mAb specific  for murine TNF, was pre- 
pared as described (20). L2.3D9 is an Ig-isotype-matched control 
mAb (hamster IgG1) for TN3.19.12. Ascites containing L2.3D9 
was provided by Dr. R. Schreiber and antibody was purified by 
a protein-A chromatography. DB-1, an IgG1 mouse anti-rat IFN-'y 
mAb which neutralizes the bioactivity of  both rat and mouse spe- 
cies, was prepared and purified using DEAE chromatography from 
ascites produced by the DB-1 hybridoma provided by Dr. P. H. M. 
van der Meide (The Primate Center, TNO, Rijswijk, the Nether- 
lands) (21). An Ig-isotype-matched control mAb 4E8/E1 (mouse 
anti-human idiotype mAb)  was  purified utilizing  a protein-A 
column from ascites provided by Dr. R. Levy  (Stanford Univer- 
sity). The bioactivity of these cytokines and mAbs were confirmed 
by in vitro assays before application in vivo. 
In'Vivo Treatment with Cytokines and Anticytokine mAbs.  NOD 
female mice from at least two separate litters were randomized and 
regrouped before treatment. Body weight was measured  every  other 
day for 3 wk. Four different treatment regimens were employed: 
(a) Newborn females  were treated intraperitoneally  every  other day 
with 20 #1 PBS only, 1/~g murine TNF (10  4 U) in 20 #1 PBS, 
4.8 #g murine  IFN-3~ (2.5  x  104  U)  in 20 #1 PBS, 20 #g/g 
bodyweight of TN3.19.12 or L2.3D9 or 100/~g/g bodyweight of 
DB-1 or 4E8/E1 from the first day after birth for 24 d. (b) 2-wk- 
old female NOD mice received intraperitoneal injections of PBS, 
1/~g TNF or 20 #g/g bodyweight TN3.19.12 every other day for 
3 wk. (c) 4-wk-old NOD females received intraperitoneal injec- 
tions of PBS, 1 #g TNF, or a constant dose (100 #g/injection) 
of TN3.19.12 every other day for 3 wk. (d) 10-wk-old NOD fe- 
males received intraperitoneal injections of PBS or 3 #g TNF for 
4 mo as described previously (12). 
Histology and Hematology.  Tissues, including salivary gland, 
thymus, spleen, adrenal gland, and stomach, were removed and 
embedded in OCT compound (Tissue-Tek, Miles, Elkhart, IN) and 
frozen  in dry ice. Cryostat sections  were  cut and sections  were stained 
with hematoxylin and eosin. Mononuclear cell counts were car- 
ried out on Giemsa-stained blood smears. 
Assessment of Insulitis and l~'abetes.  Insulitis  was assessed by 
histology. Pancreata were prepared for histology by either (a) im- 
mediate freezing of tissue in OCT compound over dry ice or in 
liquid nitrogen or (b) fixing in neutral buffered formalin and then 
embedding in paraffin.  The fixed  blocks were sectioned  and stained 
with hematoxylin and eosin. The slides were viewed by light mi- 
croscopy. The severity  ofinsulitis was assessed  as peri-insulitis (islets 
surrounded by few lymphocytes) and intraislet insulitis (lympho- 
cytic infiltration into the interior of islets). 
To assess diabetes, mice were monitored weekly for glycosuria 
using Chemstrip (Boehringer Mannheim, Indianapolis, IN). Dia- 
betes was diagnosed when mice were glycosuric for at least three 
consecutive weeks. Diabetes incidence is expressed as a percentage 
(mice with diabetes divided by total mice treated in the group). 
Cloning and Preparation of Murine l]-islet Cell Antigens.  cDNAs 
encoding the 65- and 67-kD isoform of GAD, carboxypeptidase-H 
(CPH), and peripherin were cloned from murine brain, routine 
pituitary, and murine insulinoma libraries, respectively (22). The 
cDNA of murine 60-kD heat-shock protein (HSP60) was kindly 
provided by Drs. S. Ikawa and R. Weinberg (Massachusetts Insti- 
tute of  Technology,  Cambridge, MA). The proteins were prepared 
as previously described (22). The cDNAs were engineered to en- 
code six histidine residues at the COOH terminus of  each protein. 
Recombinant proteins were expressed in a baculovirus expression 
system for GAD67, GAD65, CPH, and peripherin, and affinity 
purified using a Ni2+-conjugated resin (Invitrogen, San Diego, 
CA). HSP60 was produced in an Escherichia coli expression system 
and similarly purified. 
Immunization of Mice with Hen Egg Lysozyme or OVA.  Mice 
were injected subcutaneously in the hind footpads and at the base 
of the tail with 100 #g of hen egg lysozyme (HEL) or OVA 
emulsified with CFA. 
Lymphocyte Proliferation  Assay.  Spleen  mononuclear  cells (MNC) 
prepared from individual mice were incubated in triplicate at 5 x 
106/ml for 72 h in 0.1 ml culture medium in the presence of 20 
/zg/ml of each of the panel of 3 cell antigens. [3H]thymidine (1 
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tion of culture. Cultures were harvested using a 24-well cell har- 
vester (Cambridge Technology, Inc., Watertown,  MA).  The ex- 
tent of cell proliferation was determined by assay of the amount 
of [3H]thymidine incorporation using a beta counter (Beckman In- 
struments,  Inc., Irvine, CA) and expressed as stimulation  index 
(cpm in the presence of antigen divided by cpm in the presence 
of medium only). The culture medium contained RPMI-1640 sup- 
plemented with 1% Nutridoma-SP (Boehringer Mannheim), 0.05 
mM 2-ME (Sigma Chemical Co., St. Louis, MO), 100 U/ml peni- 
cillin,  and  100/zg/ml  streptomycin. 
ELISAforDetectionofAntigen-specificAutoantibody.  Mice were 
bled and sera of individual mice were collected. 96-well plates (Dy- 
natech, Chantilly, VA) were coated with 10/zg/ml of the recom- 
binant ~  cell antigens in 0.1 M  NaHCO3, pH 8.5, overnight at 
4~  Wells were then blocked with 0.1% gelatin in Tris-buffered 
saline,  pH 8.0, for 4 h at room temperature. Sera were added at 
a dilution of 1:100 in blocking buffer. Bound antibody was detected 
with biotin-conjugated goat anti-mouse Ig and avidinoconjugated 
alkaline-phosphatase (Sigma Chemical Co.). Reactions were devel- 
oped with nitrophenylphosphate for 30 min and absorbance at 410 
nm was read with a plate reader (model MR700; Dynatech). The 
standard error of the mean for each set of duplicates was <10%. 
Adoptive Transfer of Diabetes and Passive Transfer of Protection by 
Spleen MNC.  The acute diabetes-transfer experiments were car- 
ried out according to Wicker et al.  (23).  107 spleen  MNC from 
diabetic mice were injected intravenously into young (about 9-10- 
wk-old) male prediabetic NOD recipients.  These recipient mice 
were irradiated with gamma radiation (650 tad; 1 rad  =  0.01 Gly) 
from an x-ray source before cell injection. To assess whether mAb 
treatment generated regulatory cells that mediate the protective 
effect, a passive  transfer of protection by spleen  MNC was per- 
formed as described by Boitard et al.  (24).  Briefly,  spleen  MNC 
cells were prepared from TN3.19.12-treated and diabetes-protected 
NOD mice at 32 wk of age. 2  x  107 MNC from these mice were 
injected intravenously into irradiated recipients 24 h before transfer 
of 107 diabetogenic MNC. 
StatisticaIMethod.  Significance between data obtained from var- 
ious groups was analyzed by using the X  2 test. Probability values 
<0.05  were considered significant. 
Results 
Neonatal Administration of TNF Accelerates IDDM Onset and 
Enhances Disease Frequency, while Inhibiting TNF Activity with 
Anti-TNF mAb Prevents IDDM.  To study the early effects 
of TNF on the diabetogenic process, NOD female mice were 
injected intraperitoneally with PBS,  1/zg recombinant mu- 
fine TNF, 20/xg/g body weight of anti-TNF mAb TN3.19.12, 
or 20/xg/g body weight  of an Ig-isotype matched hamster 
mAb L2.3D9 every other day from the first day after birth 
to 24 d of age. Fig.  1 A  shows that mice treated with TNF 
began developing overt diabetes ,v4 wk earlier (at 10 wk of 
age) than control mice treated with PBS, and that all of the 
TNF-treated mice (27 out of 27) became diabetic before 20 wk 
of age. In contrast,  none of the TN3.19.12-treated  mice de- 
veloped diabetes even after 30 wk of age. The protective effect 
of anti-TNF  treatment  is  specific  since  the  control  mAb 
L2.3D9 had no effect on the disease process (Fig.  1 A). Fur- 
thermore, treatment with IFN-3,, the anti-IFN-'y mAh DB-1, 
or a control mAb for DB-1, 4E8/E1,  failed to influence the 
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Figure  1.  Administration of TNF to neonatal female mice accelerates 
IDDM onset and enhances disease incidence whereas anti-TNF prevents 
IDDM. (A) Newborn female NOD mice were injected intraperitoneally 
every other day from birth for 3 wk with PBS (F1, n =  22), 1 #g TNF 
(e, n = 27), 20 ~g/g body weight of TN3.19.12 (O, n =  19), or L2.3D9 
(A, n = 8). (B) Newborn female  NOD mice were injected intraperitoneally 
every other day from birth for 3 wk with PBS ([], n =  18), 4.8 ~g IFN-3' 
(e, n =  16) or 100 #g/g body weight of DB-1 (O, n =  7), or 4E8/E1 
(A, n = 5). Diabetes incidence was monitored weekly over the following 
30 wk. 
course of disease (Fig. 1 B). In addition, the nonautoimmune- 
prone BALB/c strain of mice, when treated neonatally with 
TNF in the same regimen, exhibited no signs of insulitis or 
diabetes  (data  not  shown). 
Since it has been shown  that TNF  can mediate cachexia 
and that neutralization of TNF activity in vivo with a poly- 
clonal anti-TNF rabbit serum can lead to retardation of mouse 
development, thymic and splenic atrophy, and lymphopenia 
(1,  18), we carefully monitored mouse development by meas- 
uring the body weight and the mortality of the mice during 
997  Yang et al. and after TNF or TN3.19.12  treatment. As shown in Fig. 
2, neonatal treatment with either TNF (2/zg/injection) or 
TN3.19.12  (20/zg/g body weight) for 3 wk had no significant 
effect on mouse development and growth, or mortality. 
To determine whether anti-TNF treatment with TN 3.19.12 
induces lymphoid atrophy and lymphopenia, several mice were 
killed after 3 wk of treatment with TN3.19.12,  and the weight 
of the thymus and the spleen,  and lymphocyte numbers in 
the blood were determined.  No significant difference in thymic 
and splenic  weight or size (data not shown) was observed 
between PBS- (thymus: 62.8  _+  5.1 g; spleen: 53.6  _+  2.8 g, 
n =  9) and TN3.19.12-treated (thymus: 57.2  +  3.8 g; spleen: 
61.4  _+  6.2 g, n  =  12) groups. No reduction of lymphocyte 
numbers in the blood (lymphopenia) was found in TN3.19.12- 
treated mice, both in terms of relative (40  +  16% vs. 37.5 
_+  12% in PBS controls, n  =  5) and absolute (29.1  _+  4.6 
vs. 28  +  5.9  x  103 lymphocytes/mm  3 in PBS controls, n = 
5) numbers. Flow cytometry analysis of thymocytes and spleen 
MNC demonstrated that the frequency of CD4 +/CD8 § vs. 
CD4-/CD8-,  CD4 §  vs. CD4-/CD8 § were com- 
parable  in TNF-, TN3.19.12-,  and PBS-treated mice (data 
not shown). 
These results indicate that the administration of TNF or 
this particular anti-TNF mAb in neonates has no significant 
cachectic  or lethal effects, or any dramatic influence on the 
development of lymphoid tissues in NOD mice. In addition, 
histological analysis  of mice treated  either with TNF  or 
TN3.19.12 revealed no detectable morphological changes or 
pathological alterations in thymus, spleen, adrenal gland, and 
stomach (data not shown). 
Age-dependent  Effect of TNF on IDDM.  To further inves- 
tigate the apparent age-dependent effect of TNF treatment 
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Figure  2.  Treatment  of neonatal  mice with TNF or TN3.19.12 does 
not effect mouse development. Female NOD  mice were injected in- 
traperitoneally  every  other day from birth for 3 wk with PBS ([-1, n = 
12), 2/zg TNF (O, n = 10), or 20/.tg/g body weight of TN3.19.12 (A, 
n = 7). Mouse  bodyweight  was monitored  every  other day over the first 
3 wk and biweekly thereafter. 
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on IDDM, female NOD  mice were treated with TNF or 
TN3.19.12 beginning at 2 or 4 wk of age. Treatment initi- 
ated at 2 wk of age resulted in enhanced disease incidence 
with TNF (100%,  nine out of nine mice at 27 wk of age) 
and prevention of disease with TN3.19.12  (0%  , zero out 
of nine mice at 34 wk of age) (Fig. 3 A). In contrast, when 
TNF treatment was initiated at 4 wk of age, a delay in the 
onset of IDDM was observed. Administering a constant dose 
(100/zg) of TN3.19.12 only partly prevented disease (about 
50%, four out of  nine mice) (Fig. 3 B). However, when animals 
were treated with 3/xg of TNF for 4 mo beginning at the 
age of 10 wk as done previously (12), the disease was reduced 
from 80 to 20% showing that TNF mediates distinct effects 
on IDDM (data not shown) that are clearly age dependent. 
TNF Potentiates the Development of Autoreactive T Lympho- 
cytes.  To elucidate the mechanisms by which neonatal ad- 
ministration of TNF induces IDDM and anti-TNF treatment 
prevents disease onset, we examined autoimmune responses 
to a panel of routine pancreatic 3  cell antigens including 
GAD67,  GAD65, peripherin,  CPH, and HSP60.  To mea- 
sure  T  cell  responses,  mice  treated  with  PBS, TNF,  or 
TN3.19.12 from birth for 3 wk, were killed at 10 wk of age, 
and splenic MNC were cultured in the presence of the 3 cell 
antigens. Fig. 4 shows that TNF-treated mice exhibited an 
enhancement of T cell responses to the 3 cell antigens rela- 
tive to the PBS-treated animals. In contrast, T cells from mice 
treated with TN3.19.12  did not respond to these antigens 
(Fig. 4), and this unresponsiveness induced by TN3.19.12 per- 
sisted for more than 6 mo (data not shown). Antibody re- 
sponses  to the panel of antigens were also measured using 
an antigen-specific  ELISA. As demonstrated in Fig. 5, TNF 
treatment led to increased antibody responses, whereas mice 
treated with anti-TNF mAb exhibited absent or very sig- 
nificantly  decreased responses to the panel of antigens. These 
results indicate that TNF is capable of promoting a diabeto- 
genic autoimmune response.  Moreover, the fact that anti-B 
cell responses can be inhibited by blocking TNF activity fur- 
ther suggests that TNF is involved in the sensitization and/or 
triggering of diabetogenic lymphocytes. 
Anti-TNF Treatment Downregulates  Autoimmune Responses 
but Does Not Induce  Immune Suppression.  The protective effect 
of TN3.19.12 may be mediated through induction of a state 
of immune unresponsiveness,  possibly through the genera- 
tion of regulatory T  cells. To rule out this possibility,  we 
measured the immune responses in TN3.19.12-treated  animals 
to two foreign antigens, HEL and OVA. 1 wk after immuni- 
zation with HEL or OVA, lymphocytes from lymph nodes 
were assayed in vitro for their reactivities  to HEL or OVA. 
Fig. 6 shows that mice treated with TN3.19.12 had enhanced 
responses to HEL and OVA relative to the PBS-treated mice. 
These findings suggest that the neonatal neutralization of 
TNF activity in vivo by mAb TN3.19.12 does not deplete 
immune competent cells or suppress their functions. If any- 
thing, the immune response to foreign antigens appears to 
be enhanced. 
It has been demonstrated that treatment of NOD mice 
with mAbs specific for MHC class II antigen can induce sup- 
pressor cells which mediate the prevention of IDDM (24). 
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Figure  3.  The effect mediated  by TNF on IDDM is age dependent. 
(A) Groups  of nine female NOD mice at 2 wk of age were injected in- 
traperitoneally  with PBS (~),  1 #g TNF (e) or 20/~g/g body weight 
of TN3.19.12  (O) every other day for 3 wk. (B) Groups of eight female 
NOD mice at 4 wk of age were injected intraperitoneally  with PBS ([3), 
1/zg TNF (e), or 100/~g TN3.19.12  (O) every other day for 3 wk. Dia- 
betes incidence  was monitored weekly over the following 30 wk. 
To determine whether a similar form of prevention was being 
induced by TN3.19.12, MNC from TN3.19.12-treated mice 
were adoptively transferred into irradiated young male NOD 
recipients before the transfer of spleen cells from diabetic 
donors. As shown in Table 1, MNC from TN3.19.12-treated 
mice failed to suppress the pathogenic effect of the transferred 
diabetogenic spleen MNC, suggesting that the observed pro- 
tective effect in the anti-TNF-treated mice is not due to the 
induction of regulatory or suppressor cells. 
Blocking  TNF Activity Inhibits Insulitis.  To gain further 
insight into the mechanism of protection induced by anti- 
TNF treatment, we examined histological sections of pan- 
creata and salivary glands of TN3.19.12-treated  mice (at 32 
wk of age). As shown in Table 2, only 27% (3 out of 11) 
of the TN3.19.12-treated  mice developed a low or moderate 
degree of insulitis compared to PBS-treated mice (100% in- 
sulitis, and 56% with severe intrainsulitis).  These data sug- 
gest that removal of TNF in vivo can inhibit  lymphocyte 
migration into the islets. Thus, the TN3.19.12-induced pro- 
tection of diabetes may result from its inhibitory effect on 
lymphocytic trafficking into the islets. It is interesting to note 
that the inflammation found in the salivary glands (sialade- 
nitis) which normally develops after 6 mo of age in NOD 
mice, remained unaffected by neonatal anti-TNF treatment 
(Table 2). This may be due to the differences in the expres- 
sion pattern of different cell adhesion molecules found in the 
inflamed islets (mainly expressing mucosal addressin cell adhe- 
sion molecule 1 [MAdCAM-1] and little peripheral vascular 
addressin,  [PNAd])  and salivary gland (mainly expressing 
PNAd but no MAdCAM-1) (25, and Yang, X.-D., S. Michie, 
R. Tisch, N. Karin, L. Steinman, and H. O. McDevitt, manu- 
script  submitted for publication). 
Discussion 
In this study, we have demonstrated that neonatal treat- 
ment of NOD mice with TNF results in an earlier onset 
and an increased incidence of IDDM, whereas blocking TNF 
activity by administering  an anti-TNF mAb prevents these 
mice from developing IDDM. It is intriguing that the TNF- 
mediated effects  on IDDM appear to be age dependent. These 
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Figure 4.  Spontaneous T cell re- 
sponses to B cell autoantigens  in 
TNF- and anti-TNF-treated mice. 
Splenic  MNC  from mice treated 
with PBS, TNF, or TN3.19.12  as 
described  in the legend to Fig.  1 
were examined for their ability to 
respond  to:  GAD67,  GAD65, 
CPH,  peripherin,  and  HSP60  in 
vitro.  The range  of cpm obtained 
in medium controls was 286-1,692. 
The  proliferative  response  is 
presented  as a stimulation  index. 
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Fig, re  5.  Antibody response to 3 cell autoantigens 
in TNF- and anti-TNF-treated mice. Mice were treated 
with PBS, TNF,  or TN3.19.12 as described  in Fig. 
1. Individual mice at 20 wk of age were assessed for 
antibody responses to: GAD65, CPH, peripherin, and 
HSP60 using an ELISA assay. Antibody detection is 
represented as units of optical density at 410 nm. 
data strongly suggest that the first 3 wk after birth are a crit- 
ical period for the initiation of the diabetogenic process in 
NOD  mice and that  interference  with immune function 
during this period can significantly alter disease outcome. This 
notion is further supported by additional lines of evidence. 
First,  NOD  mice thymectomized at birth fail to develop 
IDDM, whereas disease incidence is enhanced if animals are 
thymectomized after 3 wk of age (26-28).  Second, our re- 
cent study (22) has shown that autoimmune responses to the 
panel of 3 cell antigens in NOD mice appear temporally and 
sequentially. No response to the panel of antigens can be de- 
tected before 3 wk of age. However, responses to GAD65 
can be initially detected at 4 wk of age, suggesting that during 
the first 3 wk after birth, autoreactive lymphocytes become 
sensitized and activated in vivo. Third, in NOD mice, no 
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Figure  6.  Immune responses to the antigens HEL  or OVA in anti- 
TNF-treated  mice.  Groups  of five  to  seven  mice  were  injected  in- 
traperitoneally every other day from birth for 3 wk with PBS or 20/~g/g 
body weight of TN3.19.12.  Mice were immunized with 100 #g s.c. of 
either HEL or OVA in CFA. I wk later, lymphocytes from draining lymph 
nodes were harvested and tested for their ability to respond to HEL (20 
/~g/ml) or OVA  (100/~g/ml) in an in vitro proliferation assay. Specific 
responses  are presented as a stimulation index. 
lymphocytic infiltration  in the islets can be found before 3 
wk of age and is first detected to a minimal degree in mice 
at  ~4 wk of age (29). In addition,  in a transgenic NOD 
mouse expressing a TCR specific  for an unknown B-islet cell 
antigen, massive lymphocytic invasion of the islets begins 
abruptly at 3 wk of age (30). Taken together,  these results 
suggest that up to 3 wk of age, events occur that are critical 
in the diabetogenic process and that some of these events may 
be associated with the development ofT cells in the thymus. 
Thus, the thymus may be one of the primary target organs 
of TNF action in the newborn mouse. 
Emerging evidence implies that TNF is indeed a critical 
factor for thymic development and may also be required for 
the development of other lymphoid tissues. Early studies have 
demonstrated that TNF may be involved in thymocyte acti- 
vation  and proliferation  (31, 32), and that together with 
IFN-'y, TNF promotes the interaction between thymic epi- 
thelial cells and thymocytes (33), suggesting that TNF may 
play a role in thymocyte  growth and intrathymic cell differen- 
tiation.  Consistent  with this assumption,  Giroir et al. (17) 
have been able to demonstrate that TNF is constitutively pro- 
duced in the thymus during development.  It is interesting 
to note that it has been shown that blocking TNF (and pos- 
sibly lymphotoxin-oe) activity by administering a polyclonal 
anti-TNF antibody in utero or within the first 3 wk of life 
induces thymic and splenic atrophy, lymphopenia, and growth 
retardation  in an outbred strain of NMRI mice (18). Simi- 
larly, transgenic mice expressing high levels of soluble TNF 
receptor p55, which neutralizes TNF and lymphotoxin-ol ac- 
tivity, have defects comparable to those seen in anti-TNF- 
treated mice (Garcia, I., and P. Vassalli, unpublished data). 
Furthermore, it has been found that lymphotoxin-c~ mutant 
mice have a striking absence of peripheral lymph nodes and 
Peyer's patches, and have disordered splenic morphology (34). 
A study on TNF receptor p55 mutant mice has revealed that 
in the absence of  p55, lymphoid tissues can develop, although 
these mice have an impaired ability to clear intracellular L. 
monocytogenes infection (35). Therefore, if TNF is involved 
in the fetal development of lymphoid tissues, its action should 
be mediated by the TNF receptor p75. Together, these data 
clearly suggest that TNF and lymphotoxin-oe are among the 
essential cytokines for the development of lymphoid tissues. 
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Incidence of transfer diabetes 
Treatment  of donors  Day 10  Day 15  Day 25  Day 35 
TN3.19.12  0/10 (0%)  2/10 (20%)  8110 (80%)  10/10  (100%) 
PBS  0/10 (0%)  1/10  (10%)  8/10 (80%)  10/10  (100%) 
None  0/10 (0%)  3/10 (30%)  10/10  (100%)  10/10  (100%) 
No protection from diabetes was passively transferred  by MNC from TN3.19.12-treated mice. Groups of 10 male NOD mice at the age of 9-10 
wk were irradiated and subsequently received 2 x  107 i.v. spleen MNC from PBS or TN3.19.12-treated mice at the age of 32 wk, or no cells 
as control. The following  day, 107 diabetogenic spleen MNC were transferred intravenously  into all the recipients. Diabetes incidence was moni- 
tored every other day for 5 wk. 
Table  2.  Inhibition of Insulitis  by Anti-TNF  Treatment 
Number  of islets with infiltration 
Treatment  Insulitis incidence  No infiltration  Peri-insulitis  Intraislet-insulitis  Sialadenitis  incidence 
PBS  4/4  (100%)  33/111  (29.7%)  17/111 (15.3%)  61/111  (56.0%)  4/4 (100%) 
TN3.19.12"  3/11  (27.3%)  394/419  (94.0%)  19/419  (4.6%)  6/419  (1.4%)  7/7  (100%) 
Female NOD mice were injected intraperitoneally  every other day from birth for 3 wk with PBS or 20/zg/g body weight of TN3.19.12. At 32 
wk of age, mice were killed and pancreata and salivary  glands were assessed histologically  for insulitis or sialadenitis. 
* A highly significant  difference  of insulitis severity  between mice treated with PBS and TN3.19.12: X  2 =  258.9,/, <0.0001. 
The reason that we failed to observe an obvious developmental 
defect of lymphoid tissues in TN3.19.12-treated animals in 
the present study may be due to the fact that TN3.19.12 pre- 
dominantly neutralizes TNF although TN3.19.12 recognizes 
both TNF and lymphotoxin-ot (20). This suggests that these 
two cytokines may have distinct functions in thymocyte de- 
velopment. 
The fact that blocking TNF activity before 3 wk of age 
with the neutralizing antibody TN3.19.12 prevents insulitis 
and diabetes, clearly suggests that TNF is an essential medi- 
ator for the generation and/or activation of autoreactive lym- 
phocytes. What could be the primary target cells of TNF 
administered in vivo, and via which pathways does TNF elicit 
its effects? Based upon the present study and previous findings, 
several possibilities may be considered. First, the primary target 
of TNF could be lymphocytes. Our data have shown that 
TNF enhances autoimmune responses  to a panel of B cell 
antigens (Fig.  5).  In this scenario,  TNF could be either (a) 
modulating T cell development in the thymus, thereby leading 
to more autoreactive T cells in the periphery or (b) activating 
peripheral lymphocytes and overriding mechanisms of  periph- 
eral tolerance. Second, TNF may function by activating mac- 
rophages. As a consequence, activated macrophages may (a) 
enter the islets and begin to recruit autoreactive lymphocytes 
to the islets (36, 37); (b) potentiate processing and presenta- 
tion of/3 cell autoantigens (38,  39);  or (c) release cytokines 
such as IL-12 which promotes Thl responses that are believed 
to mediate the diabetogenic process in IDDM (40, 41). Third, 
TNF may trigger and activate the expression of adhesion mol- 
ecules on both lymphocytes and/or endothelial cells of the 
venules found in the islets (42,  43),  thereby facilitating the 
process of lymphocyte  homing to the islets. We have recently 
shown that this homing process is essential for the progres- 
sion of insulitis and diabetes  in NOD  mice (44). 
Why is the effect of TNF age dependent? It is very likely 
that the target tissues  or cells that respond to TNF do so 
in a developmentally stage-specific  manner. As mentioned 
above, a qualitative change occurs in NOD mice regarding 
the diabetogenic potential of the T cells leaving the thymus. 
Therefore, activation and enhancement of thymic function(s) 
by TNF may lead to distinct consequences  depending upon 
the developmental stage of the thymus. 
It is still puzzling how administration of TNF in adult 
animals could lead to prevention of IDDM in rodents (12, 
14, 15). TNF has been shown to be a major mediator of many 
inflammatory diseases and blocking TNF action has proved 
to be an efficient means of treatment for some inflammatory 
diseases,  including experimental allergic encephalomyelitis 
(EAE) in mice, an animal model of human multiple sclerosis, 
collagen-induced arthritis in mice, and rheumatoid arthritis 
1001  Yang et al. in patients (45-47).  It is possible  that repeated injection of 
TNF into adult animals could result in a phenomenon re- 
ferred to as "TNF tolerance" (48,  49).  TNF tolerance may 
result from the establishment of an autoantibody response 
specific for TNF and/or the stimulation of release of soluble 
TNF receptors after injection of large doses of TNF for an 
extended period of time (e.g.,  3 #g/injection every 2 d for 
4  mo)  (12). Both  anti-TNF  antibody and  soluble  TNF 
receptors may block TNF activity in vivo and in turn pre- 
vent disease. It has been reported that anti-cytokine autoan- 
tibodies such as anti-TNF, anti-IL-lot, and anti-IL-6 can be 
detected in patients with immunoinflammatory and infec- 
tious diseases,  as well as in normal individuals (50-52).  It 
is interesting to note that some of these autoantibodies have 
been shown to be able to specifically inhibit bioactivities of 
the respective cytokines in vitro (53).  Recently, Bemelmans 
et al. (54) have reported that injection of recombinant TNF 
can result in the release of the extracellular parts of both 55- 
and 75-kD TNF receptors, namely the soluble TNF receptors 
in vivo. These potential mechanisms are currently under in- 
vestigation. In addition, it has been shown in the EAE model, 
that treatment of mice with TN3.19.12  did not appear  to 
deplete cells expressing TNF on the surface, suggesting that 
TN3.19.12 does not function by depleting TNF expressing 
lymphocytes (45). 
The partial protective effect observed when TN3.19.12 is 
initially injected into 4-wk-old mice may be due to insufficient 
amounts of antibody (100 #g/injection, which was not based 
on the body weight) (Fig. 3). The treatment with TN3.19.12 
in adult animals has been shown to enhance insulitis severity 
(55).  However,  in  this  previous  study (55),  the  effect  of 
TN3.19.12 was investigated on insulitis but not on sponta- 
neous diabetes.  The degree of insulitis severity is not neces- 
sarily correlated with the incidence of diabetes. For instance, 
male NOD mice develop very severe insulitis but only 10-20% 
become diabetic. 
The present study on the neonatal effect of TNF on IDDM 
in mice clearly demonstrates that TNF is a proinflammatory 
cytokine that is involved in the immunopathogenic process 
of IDDM. TNF appears to have distinct effects on diabeto- 
genic process  depending upon the developmental stages of 
the target tissue or cell.  The protective effect of anti-TNF 
treatment may have implications for the development of a 
cytokine or cytokine receptor-based prevention of human 
IDDM. 
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